Pre-and polyfluoroalkyl substances (PFAS) are known as ‘forever chemicals’ due to their long half-life and high resistance to degradation. PFAS are often used in medical devices because of their ‘non-stick’ quality. However, these chemicals are likely to be banned in Europe from 2025 as a result of their toxicity to humans and the environment. An EU-wide ban will force manufacturers to seek out PFAS-alternatives. This presents an upside for manufacturers of PFAS-free materials but may also introduce supply-chain disruptions and regulatory hurdles in the medium-term.

In this piece, Marwood analyses the regulatory changes on the horizon in the medical device sector and the potential impact the PFAS ban may have on existing or potential assets.

To receive a copy of the full report, please contact us.